Exploristics' Investment Aims to Revolutionise Clinical Trials
Belfast-based data analysis company, Exploristics is investing in eight additional jobs and R&D to enhance its competitiveness within the healthcare market.
Invest Northern Ireland has a long standing relationship with the business and has supported the development of its new software tool, KERUS™ Cloud which launched to market last week. The new product has the potential to triple the company’s turnover over the next two years and transform the speed and efficiency with which new medicines are brought to market.
Invest NI support is enabling the business to recruit new staff across a range of roles and also undertake R&D, part funded by the European Regional Development Fund, to expand its diagnostic capabilities to secure new business.
Invest NI’s support is enabling Exploristics to fully implement its project at the scale and timeframe needed to growth the business and achieve its growth targets in a sustainable manner- Grainne McVeigh, Invest NI
Speaking following a visit to the company’s premises, Grainne McVeigh, Invest NI’s Director of Life Sciences and Scaling, said: “Despite being a relatively new business, Exploristics is gaining market traction and developing an excellent reputation among large pharmaceutical companies.
“Life and Health Sciences is a priority sector for the Northern Ireland economy and the eight new jobs being recruited at the business are high salaried, skilled positions.
“Invest NI’s support is enabling Exploristics to fully implement its project at the scale and timeframe needed to growth the business and achieve its growth targets in a sustainable manner.”
Dr Aiden Flynn, CEO of Exploristics, founded the business in 2009 and has extensive experience in pharmaceutical development work with major pharma companies. He added: “Investing in additional staff and R&D was paramount for us to maintain a competitive advantage and fulfil our growth potential.
“The commercialisation and launch of KERUS™ Cloud is a significant achievement for the business that allows us to expand our customer base and exploit the full commercial opportunities this software presents for us in the personalised medicine market.”
The company’s target market is the pharmaceutical, biotech and medical device industries across Europe, USA, Middle East, India and Australia. Its cloud-based statistical and big data analytics platform, KERUS™ Cloud, gives researchers the chance to improve the success of their studies and transform the speed and efficiency with which new medicines are brought to market.
Dr Flynn added: “Invest NI’s ongoing support and advice has been central to our development to date and the team continues to act as trusted partner for us as we look to scale the business to meet a known market need. We have benefited from assistance across a range of areas including e-business systems, export marketing, skills and product development as well as job creation. We are more effective and competitive as a result, poised to respond quickly to the data requirements of our clients.”